In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Globally, Treat Locally: Serono Buys Rights to InDex's Kappaproct

Executive Summary

In-licensing Phase II ulcerative colitis drug Kappaproct from Swedish biotech InDex Pharmaceuticals wasn't the major move observers have been waiting for from Serono; it certainly doesn't reduce the Swiss firm's dependence on Rebif. But the $35 million deal endorses InDex's localized approach to antisense therapy, a failure-ridden area that many firms have given up on.

Related Content

Gilead's Metamorphoses


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts